Fibroblast growth factor receptor 4 protein expression and clinicopathological features in gastric cancer

Table 2 Relationship between different clinicopathological characteristics and prognosis

Clinicopathological characteristics	FGFR4 positive		FGFR4 negative		χ2	P value
	Median survival time (mo)	5-yr survival rate	Median survival time (mo)	5-yr survival rate
Gender
Male	27	27.4	47	36.7	1.1198	0.2900
Female	43	42.2	46	44.8	0.0000	0.9967
Age (yr)
< 60	31	23.9	35	30.0	0.4080	0.5230
≥ 60	44	36.1	52	46.0	0.6206	0.4308
Tumor size
≤ 3 cm	42	40.4	60	69.0	5.5033	0.0190
> 3 cm	22	24.8	24	26.2	0.0746	0.7848
Tumor location
U	18	31.1	38	31.4	0.7164	0.3973
M	43	31.5	46	38.1	0.0225	0.8807
L	35	29.1	52	42.5	1.1274	0.2883
Tumor differentiation
Poor	17	23.4	35	20.1	2.2622	0.1326
Well	31	47.0	56	62.1	7.9757	0.0047
TNM stages
I + II	56	57.7	60	69.6	1.3128	0.2519
III + IV	15	3.5	19	10.6	0.5328	0.4654
T
T1 + T2	54	55.8	60	82.1	4.8827	0.0271
T3 + T4	22	19.4	18	21.3	0.0479	0.8268
N
N0	58	67.4	60	75.0	0.4856	0.4859
N1 + N2 + N3	18	10.1	25	24.3	2.5385	0.1111
M
0	43	35.3	52	45.4	1.2078	0.2718
1	9	0.0	12	0.0	0.4042	0.5249
Neural I invasion
Yes	19	38.9	56	18.8	2.1949	0.1385
No	36	30.2	49	43.3	3.1118	0.0777
Vascular I invasion
Yes	21	13.8	22	14.3	0.0507	0.8219
No	42	34.0	54	46.2	1.7283	0.1886

FGFR4: Fibroblast growth factor receptor 4; TNM: Tumor-node-metastasis.